U.S. paves way for Novartis to copy Amgen biotech drug

(Reuters) - U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for patients with low white blood cell counts.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news